Work

Assessing the value of cemiplimab for adults with advanced cutaneous squamous cell carcinoma (CSCC): A cost-effectiveness analysis.

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.e19397

Authors: Eleanor Paul, Andreas Kuznik, Sam Keeping, Chieh-I Chen, Medha Sasane, Yingxin Xu, Gerasimos Konidaris, Kokuvi Atsou, Dieter Ayers, Emily S Ruiz, Nikhil I. Khushalani, Shannon Cope

Institutions: Regeneron (United States), Sanofi (United States), Inserm, Sorbonne Université, Institut Pierre Louis d‘Épidémiologie et de Santé Publique, Brigham and Women's Hospital, Harvard University, Moffitt Cancer Center

Language: English

Topic: Health Systems, Economic Evaluations, Quality of Life

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3028701299

Cites:

Cited by:

Related to: 10